Galectins: Regulators of acute and chronic inflammation

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 158-182

  Liu, Fu Tong ^a   Rabinovich, Gabriel A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Galectin; Glycans; Immunity; Inflammation; Lectin

Indexed keywords

ECALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 4; GALECTIN 8; GLYCOPROTEIN;

ADAPTIVE IMMUNITY; ALLERGY; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; EFFECTOR CELL; ENDOCYTOSIS; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFECTION; INFLAMMATION; INNATE IMMUNITY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA; MUS;

EID: 75749101401     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05131.x     Document Type: Review

References (175)

1. Liu, F.T., R.J. Patterson & J.L. Wang. 2002. Intracellular functions of galectins. Biochim. Biophys. Acta 1572: 263-273.
2. Yang, R.Y., G.A. Rabinovich & F.T. Liu. 2008. Galectins: structure, function and therapeutic potential. Expert Rev. Mol. Med. 10: e17.
3. Rabinovich, G.A. et al. 2007. An emerging role for galectins in tuning the immune response: lessons from experimentalmodels of inflammatory disease, autoimmunity and cancer. Scand. J. Immunol. 66: 143-158.
4. La, M. et al. 2003. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation.Am. J. Pathol. 163: 1505-1515.
5. Cooper, D., L.V. Norling & M. Perretti. 2008. Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 83: 1459-1466.
6. Stowell, S.R. et al. 2007. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109: 219-227.
7. Karmakar, S. et al. 2008. Galectin-1 signaling in leukocytes requires expression of complex-type N-glycans. Glycobiology 18: 770-778.
8. Stowell, S.R. et al. 2009. Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol. Biol. Cell. 20: 1408-1418.
9. Almkvist, J. et al. 2002. Activation of the neutrophil nicotinamide adenine dinucleotide phosphate oxidase by galectin-1. J. Immunol. 168: 4034-4041.
10. Yamaoka, A. et al. 1995. A human lectin, galectin- 3 (eBP/Mac-2), stimulates superoxide production by neutrophils. J. Immunol. 154: 3479-3487.
11. Karlsson, A. et al. 1998. Galectin-3 activates the NADPH-oxidase in exudated but not peripheral blood neutrophils. Blood 91: 3430-3438.
12. Almkvist, J. et al. 2001. Lipopolysaccharide-induced gelatinase granule mobilization primes neutrophils for activation by galectin-3 and formylmethionyl-Leu-Phe. Infect. Immun. 69: 832-837.
13. Farnworth, S.L. et al. 2008. Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function. Am. J. Pathol. 172: 395-405.
14. Kuwabara, I. & F.T. Liu. 1996. Galectin-3 promotes adhesion of human neutrophils to laminin. J. Immunol. 156: 3939-3944.
15. Sato, S. et al. 2002. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J. Immunol. 168: 1813-1822.
16. Stowell, S.R. et al. 2008. Differential roles of galectin- 1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J. Immunol. 180: 3091-3102.
17. Fernandez, G.C. et al. 2005. Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology 15: 519-527.
18. Nishi, N. et al. 2003. Galectin-8 modulates neutrophil function via interaction with integrin alphaM. Glycobiology 13: 755-763.
19. Rabinovich, G.A. et al. 2000. Evidence of a role for galectin-1 in acute inflammation. Eur J. Immunol. 30: 1331-1339.
20. Correa, S.G. et al. 2003. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology 13: 119-128.
21. Barrionuevo, P. et al. 2007. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J. Immunol. 178: 436-445.
22. Zuniga, E. et al. 2001. Regulated expression and effect of galectin-1 on Trypanosoma cruzi-infected macrophages: modulation of microbicidal activity and survival. Infect. Immun. 69: 6804-6812.
23. Mercier, S. et al. 2008. Galectin-1 promotes HIV-1 infectivity in macrophages through stabilization of viral adsorption. Virology 371: 121-129.
24. Liu, F.T. et al. 1995. Expression and function of galectin- 3, a b-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol. 147: 1016-1029.
25. Sano, H. et al. 2000. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J. Immunol. 165: 2156-2164.
26. Karlsson, A. et al. 2009. Galectin-3 functions as an opsonin and enhances themacrophage clearance of apoptotic neutrophils. Glycobiology 19: 16-20.
27. Rotshenker, S. 2009. The Role of Galectin-3/MAC-2 in the Activation of the Innate-Immune Function of Phagocytosis inMicroglia in Injury and Disease. J.Mol. Neurosci. 39: 99-103.
28. Sano,H. et al. 2003. Critical role of galectin-3 in phagocytosis by macrophages. J. Clin. Invest. 112: 389-397.
29. Beatty, W.L. et al. 2002. Association of a macrophage galactoside-binding protein with Mycobacteriumcontaining phagosomes. Cell Microbiol. 4: 167-176.
30. Jin, R. et al. 2006.Human monocytes recognize porcine endothelium via the interaction of galectin 3 and alpha- GAL. J. Immunol. 177: 1289-1295.
31. MacKinnon, A.C. et al. 2008. Regulation of alternative macrophage activation by galectin-3. J. Immunol. 180: 2650-2658.
32. Li, Y. et al. 2008. Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J. Immunol. 181: 2781-2789.
33. Stowell, S.R. et al. 2008. Dimeric Galectin-8 induces phosphatidylserine exposure in leukocytes through polylactosamine recognition by the C-terminal domain. J. Biol. Chem. 283: 20547-20559.
34. Kashio, Y. et al. 2003. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 170: 3631-3636.
35. Matsuura, A. et al. 2009. Intracellular galectin-9 activates inflammatory cytokines in monocytes. GenesCells 14: 511-521.
36. Fulcher, J.A. et al. 2006. Galectin-1-matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. J. Immunol. 177: 216-226
37. Blois, S.M. et al. 2007. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 13: 1450-1457.
38. Bernardes, E.S. et al. 2006. Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am. J. Pathol. 168: 1910-1920.
39. Saegusa, J. et al. 2009. Galectin-3 is critical for the development of the allergic inflammatory response in a mouse model of atopic dermatitis. Am. J. Pathol. 174: 922-931.
40. Breuilh, L. et al. 2007. Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect. Immun. 75: 5148-5157.
41. Hsu, D.K. et al. 2009. Endogenous Galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J. Invest. Dermatol. 129: 573-583.
42. Vray, B. et al. 2004. Up-regulation of galectin-3 and its ligands by Trypanosoma cruzi infection with modulation of adhesion and migration of murine dendritic cells. Glycobiology 14: 647-657.
43. Bax, M. et al. 2007. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J. Immunol. 179: 8216-8224.
44. Dai, S.Y. et al. 2005. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J. Immunol. 175: 2974-2981.
45. Suzuki, Y. et al. 2008. Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition. Biochim. Biophys. Acta 1783: 924-934.
46. Frigeri, L.G., R.I. Zuberi & F.T. Liu. 1993. eBP, a-- galactoside-binding animal lectin, recognizes IgE receptor (FceRI) and activates mast cells. Biochemistry 32: 7644-7649.
47. Zuberi, R.I., L.G. Frigeri & F.T. Liu. 1994. Activation of rat basophilic leukemia cells by eBP, an IgE- binding endogenous lectin. Cell Immunol. 156: 1-12.
48. Chen, H.Y. et al. 2006. Role of Galectin-3 in mast cell functions: Galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression. J. Immunol. 177: 4991-4997.
49. Truong, M.J. et al. 1993. IgE-binding molecules (Mac- 2/eBP) expressed by human eosinophils Implication in IgE-dependent eosinophil cytotoxicity. Eur J. Immunol. 23: 3230-3235.
50. Cortegano, I. et al. 1998. Galectin-3 down-regulates IL- 5 gene expression on different cell types. J. Immunol. 161: 385-389.
51. Cortegano, I. et al. 2000. Interaction between galectin- 3 and FcgammaRII induces down-regulation of IL-5 gene: implication of the promoter sequence IL-5REIII. Glycobiology 10: 237-242.
52. Rao, S.P. et al. 2007. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J. Immunol. 179: 7800-7807.
53. Matsumoto, R. et al. 1998.Humanecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 273: 16976-16984. (Pubitemid 28311730)
54. Matsumoto, R. et al. 2002. Biological activities of ecalectin: a novel eosinophil-activating factor. J. Immunol. 168: 1961-1967.
55. Saita, N. et al. 2002. Association of galectin-9 with eosinophil apoptosis. Int. Arch. Allergy Immunol. 128: 42-50.
56. Asakura, H. et al. 2002. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J. Immunol. 169: 5912-5918.
57. Liu, S.D. et al. 2008. Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes. Blood 112: 120-130.
58. Chung, C.D. et al. 2000. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165: 3722-3729.
59. Endharti, A.T. et al. 2005. Galectin-1 supports survival of naive T cells without promoting cell proliferation. Eur J. Immunol. 35: 86-97.
60. Silva-Monteiro, E. et al. 2007. Altered expression of Galectin-3 induces cortical thymocyte depletion and premature exit of immature thymocytes during trypanosoma cruzi infection. Am. J. Pathol. 170: 546-556.
61. Rabinovich,G.A. et al. 1999. Specific inhibition ofT-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97: 100-106.
62. Rabinovich, G.A. et al. 2002. Induction of allogenic Tcell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptoticmechanisms. CellDeathDiffer. 9: 661-670.
63. Van Der Leij, J. et al. 2007. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol. Immunol. 44: 506-513.
64. Motran, C.C. et al. 2008. Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur J. Immunol. 38: 3015-3027.
65. Juszczynski,P. et al. 2007. TheAP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 104: 13134-13139.
66. Gandhi,M.K. et al. 2007. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110: 1326-1329.
67. Toscano, M.A. et al. 2006. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J. Immunol. 176: 6323-6332.
68. Perone, M.J. et al. 2009. Suppression of autoimmune diabetes by soluble galectin-1. J. Immunol. 182: 2641-2653.
69. He, J. & L.G. Baum. 2006. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab. Invest. 86: 578-590.
70. Norling, L.V. et al. 2008. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 22: 682-690.
71. Perillo, N.L. et al. 1995. Apoptosis of T cells mediated by galectin-1. Nature 378: 736-739.
72. Rabinovich, G.A. et al. 1997. Specific inhibition of lymphocyte proliferation and induction of apoptosis by CLL-I, a--galactoside-binding lectin. J. Biochem. (Tokyo) 122: 365-373.
73. Rabinovich,G.A. et al. 1998.Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: Biochemical and functional characterization. J. Immunol. 160: 4831-4840.
74. Rabinovich, G.A. et al. 2000. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ. 7: 747-753.
75. Kopcow, H.D. et al. 2008. T cell apoptosis at the maternal-fetal interface in early human pregnancy, involvement of galectin-1. Proc. Natl. Acad. Sci. USA 105: 18472-18477.
76. Pace, K.E. et al. 1999. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 163: 3801-3811.
77. Nguyen, J.T. et al. 2001. CD45 modulates galectin-1- induced T cell death: regulation by expression of core 2 O-glycans. J. Immunol. 167: 5697-5707.
78. Hahn, H.P. et al. 2004. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ. 11: 1277-1286.
79. Matarrese, P. et al. 2005. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem. 280: 6969-6985.
80. Ion, G. et al. 2006. Acid sphingomyelinase mediated release of ceramide is essential to trigger the mitochondrial pathway of apoptosis by galectin-1. Cell Signal. 18: 1887-1896.
81. Stillman, B.N. et al. 2006. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176: 778-789.
82. Gonzalez, M.I. et al. 2005. Regulated expression of galectin-1 after in vitro productive infection with herpes simplex virus type 1: implications for T cell apoptosis. Int. J. Immunopathol. Pharmacol. 18: 615-623.
83. Mercer, N. et al. 2009. Duodenal intraepithelial lymphocytes of children with cow milk allergy preferentially bind the glycan-binding protein galectin-3. Int. J. Immunopathol. Pharmacol. 22: 207-217.
84. Toscano, M.A. et al. 2007. Differential glycosylation of T(H)1, T(H)2 and T(H)-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8: 825-834.
85. Brandt, B. et al. 2008. Galectin-1 induced activation of the apoptotic death-receptor pathway in human Jurkat T lymphocytes. Histochem. Cell Biol. 129: 599-609.
86. Nguyen, J.T. et al. 2001. CD45 modulates galectin-1- induced T cell death: regulation by expression of core 2 O-glycans. J. Immunol. 167: 5697-5707.
87. Walzel, H. et al. 2000. Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells. Glycobiology. 10: 131-140.
88. Amano,M.et al. 2003. The ST6Gal I sialyltransferase selectivelymodifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J. Biol. Chem. 278: 7469-7475.
89. Hernandez, J.D. et al. 2006. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J. Immunol. 177: 5328-5336.
90. Cabrera, P.V. et al. 2006.Haploinsufficiency of C2GnTI glycosyltransferase renders T lymphoma cells resistant to cell death. Blood 108: 2399-2406.
91. Blaser, C. et al. 1998.--galactoside binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J. Immunol. 28: 2311-2319.
92. Fuertes, M.B. et al. 2004. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase.Mol Cell Biochem. 267: 177-185.
93. Liu, S.D. et al. 2009. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size. J. Immunol. 182: 5283-5295.
94. Hsu, D.K. et al. 1996. Human T lymphotropic virus- 1 infection of human T lymphocytes induces expression of the b-galactose-binding lectin, galectin-3. Am. J. Pathol. 148: 1661-1670.
95. Dong, S. & R.C. Hughes. 1996. Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells. FEBS Lett. 395: 165-169.
96. Fukumori, T. et al. 2003. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63: 8302-8311.
97. Ahmad, N. et al. 2004. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 279: 10841-10847.
98. Bourne, Y. et al. 1994. Crosslinking of mammalian lectin (galectin-1) by complex biantennary saccharides. Struc. Biol. 1: 863-1860
99. Yang, R.Y., D.K. Hsu & F.T. Liu. 1996. Expression of galectin-3 modulates T cell growth and apoptosis. Proc. Natl. Acad. Sci. USA 93: 6737-6742.
100. Matarrese, P. et al. 2000. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett. 473: 311-315.
101. Yu, F. et al. 2002. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 277: 15819-15827.
102. Joo, H.G. et al. 2001. Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J. Leukoc. Biol. 69: 555-564.
103. Demetriou, M. et al. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 Nglycosylation. Nature 409: 733-779.
104. Demotte, N. et al. 2008. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28: 414-424.
105. Hokama, A. et al. 2004. Induced reactivity of intestinal CD4+ T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20: 681-693.
106. Paclik, D. et al. 2008. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS ONE 3: e2629.
107. Norambuena,A. et al. 2009. Galectin-8 induces apoptosis in jurkat T cells by phosphatidic acid-mediated ERK 1/2 activation supported by PKA down regulation. J. Biol. Chem. 284: 12670-12679.
108. Tribulatti, M.V. et al. 2007. Galectin-8 induces apoptosis in the CD4(high)CD8(high) thymocyte subpopulation. Glycobiology 17: 1404-1412.
109. Yamamoto, H. et al. 2008. Induction of cell adhesion by galectin-8 and its target molecules in Jurkat T-cells. J. Biochem. 143: 311-324.
110. Wada, J. et al. 1997. Developmental regulation, expression, and apoptotic potential of galectin-9, a-- galactoside binding lectin. J Clin Invest. 99: 2452-2461.
111. Zhu, C. et al. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245-1252.
112. Sugimoto, N. et al. 2006. Foxp3-dependent and - independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18: 1197-1209.
113. Garin, M.I. et al. 2007. Galectin-1: a key effector of regulation mediated byCD4+CD25+ Tcells. Blood 109: 2058-2065.
114. Wang, J. et al. 2009. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J. Immunol. 182: 4036-4045.
115. Kubach, J. et al. 2007.HumanCD4+CD25+regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110: 1550-1558.
116. Zuniga, E. et al. 2001. Regulated expression of galectin- 1 during B-cell activation and implications for T-cell apoptosis. J. Leukoc. Biol. 70: 73-79.
117. Gauthier, L. et al. 2002. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc. Natl. Acad. Sci. USA 99: 13014-13019.
118. Rossi, B. et al. 2006. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation. J. Immunol. 177: 796-803.
119. Espeli, M. et al. 2009. Impaired B cell development at the pre-BII cell stage in galectin-1 deficient mice due to inefficient pre-BII-stromal cell interactions. Blood. 113: 5878-5886.
120. Tsai, C.M. et al. 2008. Galectin-1 promotes immunoglobulin production during plasma cell differentiation. J. Immunol. 181: 4570-4579.
121. Tabrizi, S.J. et al. 2009. T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J. Immunol. 182: 1490-1499.
122. Acosta-Rodriguez, E.V. et al. 2004. Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J. Immunol. 172: 493-502.
123. Hoyer, K.K. et al. 2004. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am. J. Pathol. 164: 893-902.
124. Okudaira, T. et al. 2007. Amodified version of galectin- 9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T cell lines. Int. J. Cancer 120: 2251-2261.
125. He, J. & L.G. Baum. 2004. Presentation of galectin-1 by extracellular matrix triggers T cell death. J. Biol. Chem. 279: 4705-4712.
126. Denzer, K. et al. 2000. Exosome: frominternal vesicle of themultivesicular body to intercellular signaling device. J. Cell Sci. 113(Pt 19): 3365-3374.
127. Thery, C. et al. 2001. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166: 7309-7318.
128. Keryer-Bibens, C. et al. 2006. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6: 283.
129. Klibi, J. et al. 2009.Blood diffusion andTh1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957-1966.
130. Delacour, D. et al. 2006. Requirement for galectin-3 in apical protein sorting. Curr. Biol. 16: 408-414.
131. Delacour, D. et al. 2008. Loss of galectin-3 impairs membrane polarisation of mouse enterocytes in vivo. J. Cell Sci. 121: 458-465.
132. Pacienza,N. et al. 2008. Theimmunoregulatory glycanbinding protein galectin-1 triggers human platelet activation. FASEB J. 22: 1113-1123.
133. Hsu, D.K. et al. 2000. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Amer. J. Pathol. 156: 1073-1083.
134. Colnot, C. et al. 1998. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-nullmutant mice. Immunology 94: 290-296.
135. Loser, K. et al. 2009. Galectin-2 suppresses contact allergy by inducing apoptosis in activated CD8+ T cells. J. Immunol. 182: 5419-5429.
136. Zuberi, R.I. et al. 2004. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am. J. Pathol. 165: 2045-2053.
137. del Pozo, V. et al. 2002. Gene therapy with galectin- 3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation. Am. J. Respir. Crit. Care Med. 166: 732-737.
138. Lopez, E. et al. 2006. Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J. Immunol. 176: 1943-1950.
139. Katoh, S. et al. 2007. Galectin-9 inhibits CD44- hyaluronan interaction and suppresses amurine model of allergic asthma. Am. J. Respir. Crit. Care Med. 176: 27-35.
140. Fukushima, A. et al. 2008. Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice. Int. Arch. Allergy Immunol. 146: 36-43.
141. Levi, G., R. Tarrab-Hazdai & V.I. Teichberg. 1983. Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J. Immunol. 13: 500-507.
142. Offner, H. et al. 1990. Recombinant human betagalactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 28: 177-184.
143. Rabinovich, G. et al. 1999. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190: 385-397.
144. Santucci, L. et al. 2000. Galectin-1 exerts immunomodulatory and protective effects on concanavalin Ainduced hepatitis in mice. Hepatology 31: 399-406.
145. Santucci, L. et al. 2003. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124: 1381-1394.
146. Baum, L.G. et al. 2003. Amelioration of graft versus host disease by galectin-1. Clin. Immunol. (Orlando, Fla.) 109: 295-307.
147. Perone,M.J. et al. 2006. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J. Immunol. 177: 5278-5289.
148. Jiang, H.R. et al. 2009. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J. Immunol. 182: 1167-1173.
149. Pugliese, G. et al. 2001. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. 15: 2471-2479.
150. Iacobini, C. et al. 2004. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J. 18: 1773-1775.
151. Iacobini, C. et al. 2005. Development of agedependent glomerular lesions in galectin-3/AGEreceptor- 3 knockout mice. Am. J. Physiol. Renal Physiol. 289: F611-621.
152. Stitt, A.W. et al. 2005. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54: 785-794.
153. Mensah-Brown, E.P. et al. 2009. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin. Immunol. (Orlando, Fla.) 130: 83-88.
154. Seki, M. et al. 2007. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum. 56: 3968-3976.
155. Seki, M. et al. 2008. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. (Orlando, Fla.) 127: 78-88.
156. Tsuchiyama, Y. et al. 2000. Efficacy of galectins in the amelioration of nephrotoxic serum nephritis inWistar Kyoto rats. Kidney Int. 58: 1941-1952.
157. Romero, M.D. et al. 2006. Circulating anti-galectin-1 antibodies are associated with the severity of ocular disease in autoimmune and infectious uveitis. Invest. Ophthalmol. Vis. Sci. 47:1550-1556.
158. Massardo, L. et al. 2009. Autoantibodies against galectin-8: their specificity, associationwith lymphopenia in systemic lupus erythematosus and detection in rheumatoid arthritis and acute inflammation. Lupus 18:539-546.
159. Ozaki, K. et al. 2004. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 429: 72-75.
160. Nachtigal, M. et al. 1998. Galectin-3 expression in human atherosclerotic lesions. Am. J. Pathol. 152: 1199-1208. (Pubitemid 28221873)
161. Nachtigal, M., A. Ghaffar & E.P.Mayer. 2008. Galectin- 3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am. J. Pathol. 172: 247-255.
162. Terness, P. et al. 2007. Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatoryTcells.Am. J. Reprod. Immunol. 58: 238-254.
163. Rubinstein, N. et al. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251.
164. Rodig, S.J. et al. 2008. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin. Cancer Res. 14: 3338-3344.
165. Valenzuela, H.F. et al. 2007. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res. 67: 6155-6162.
166. Rabinovich,G.A. et al. 2006. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16: 210-220.
167. Ingrassia, L. et al. 2006.Anti-galectin compounds as potential anti-cancer drugs. Curr. Med. Chem. 13: 3513-3527.
168. Peng,W. et al. 2008. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 68: 7228-7236.
169. Nagahara, K. et al. 2008. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 181: 7660-7669.
170. Nobumoto, A. et al. 2009. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic celllike phenotypes that activate NK cells in tumor-bearing mice. Clin. Immunol. (Orlando, Fla.) 130: 322-330.
171. Nieminen, J. et al. 2008. Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J. Immunol. 180: 2466-2473.
172. Ferraz, L.C. et al. 2008. Lack of galectin-3 alters the balance of innate immune cytokines and confers resistance to Rhodococcus equi infection. Eur J. Immunol. 38: 2762-2775.
173. Ruas, L.P. et al. 2009. Lack of galectin-3 drives response to Paracoccidioides brasiliensis toward a Th2-biased immunity. PLoS ONE 4: e4519.
174. Tsuboi, Y. et al. 2007. Galectin-9 protects mice fromthe Shwartzman reaction by attracting prostaglandin E2- producing polymorphonuclear leukocytes. Clin. Immunol. (Orlando, Fla.) 124: 221-233.
175. Sehrawat, S. et al. 2009. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J. Immunol. 182: 3191-3201.